Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.
To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
GCR Live: Law Leaders Global 2025
Speaking Engagement
Antitrust
Evidence for Trial Lawyers: Motions, Introducing Evidence, and Objections
Speaking Engagement
Intellectual Property
NYC Bar Trade Secrets Symposium 2024: Navigating the Law of Trade Secrets and Restrictive Covenants
Speaking Engagement
Intellectual Property
Stakeholders 24th Annual CYOC Career Development Conference
Sponsorship
IAM Connect Patent Policy and Litigation Conference 2024
Speaking Engagement
Intellectual Property
CompLaw 33rd Annual Advanced EU Brussels Conference
Speaking Engagement
Jason Murata Named a Profiles in Diversity Journal Diverse Lawyers Making a Difference Award Winner
Awards & Recognitions
Intellectual Property
AIC General Counsel Day 2024
Speaking Engagement
Antitrust
ALM General Counsel Conference East 2024
Speaking Engagement
Antitrust
Global M&A Antitrust Outlook: Trends Shaping Enforcement Strategies
Speaking Engagement
Antitrust